CD68 antibody - HS-460 003

CD68 is a marker for macrophages and activated microglia
Rabbit polyclonal purified antibody
Cat. No.: HS-460 003
Amount: 50 µg
Price: $370.00
Cat. No. HS-460 003 50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 1000 (AP staining) gallery  
IP: not tested yet
ICC: not tested yet
IHC: 1 : 2000 up to 1 : 5000 (see remarks) gallery  
IHC-P: 1 : 1000 up to 1 : 4000 gallery  
Immunogen Synthetic peptide corresponding to residues surrounding AA 100 of mouse CD68 (UniProt Id: P31996)
Reactivity Reacts with: mouse (P31996), rat.
No signal: human (P34810).
Other species not tested yet.
Remarks

IHC: Heat-mediated antigen retrieval (in citrate buffer pH 6) is required for immunohistochemical staining

Data sheet hs-460_003.pdf
Cat. No.: HS-460 003
Amount: 50 µg
Price: $370.00

Immunodetection of CD68 (red) and F4/80 (green) positive macrophages in a mouse spleen.

Background

CD68, also called Lamp-4 in humans or macrosialin in mice, is a highly glycosylated type I transmembrane protein that belongs to the lysosome associated membrane protein (LAMP) family (1). CD68 expression is increased in cells associated with elevated phagocytic and degradative activity. High CD68 expression is detected in cells of the mononuclear phagocyte lineage including macrophages, osteoclasts, and myeloid dendritic cells (2). CD68 is a marker of activated microglia and only expressed at low levels in resting microglia (3). Staining for CD68 is predominantly intracellular, only 10 -15% of it is found on the cell surface. In oncology research, CD68 is the major biomarker for quantification of tumor-associated macrophages (TAMs) (4). High infiltration of CD68+ macrophages is an independent prognostic factor for overall survival in several tumor entities (5).